News >

Neratinib Promising for Early-Stage HER2+ Breast Cancer, But Has Caveats

Kristi Rosa
Published: Wednesday, Nov 14, 2018

Mohammed Rahman, MD

Mohammed Rahman, MD

The pan-HER TKI neratinib (Nerlynx) demonstrates efficacy as an adjuvant therapy for patients with HER2-positive breast cancer; however, the associated adverse events (AEs) provide some patient selection challenges, explained Mohammed Rahman, MD.

“I think all-in-all, it’s an attractive treatment. The only downside of it is gastrointestinal toxicity—the diarrhea rate in the ExteNET trial was almost 90%, but more importantly, grade 3 diarrhea was close to 39% or 40%,” said Rahman. “However, if doctors are very aggressive with antidiarrheal management, these [events] can be managed easily and effectively. We can actually get the numbers down with various remedies to maybe single-digit figures in terms of grade 3 diarrhea toxicity.”

The FDA approved neratinib (Nerlynx) in July 2017 to prevent recurrence in patients with early-stage HER2-positive breast cancer who had completed at least 1 year of adjuvant therapy with trastuzumab (Herceptin).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication